@article { author = {Pouyanfar, Anis and Imannezhad, Shima and Nasiri, Mona and Yadollahi, Negin and Akhavan, Hossein}, title = {Covid-19 in Children with Emphasis on Prevention: A Rapid Review}, journal = {Health Providers}, volume = {1}, number = {1}, pages = {13-20}, year = {2021}, publisher = {SinaWeb}, issn = {2820-9192}, eissn = {2820-9192}, doi = {10.22034/hp.2022.148878}, abstract = {      Children of all ages can be infected with coronavirus disease (COVID-19), and experience complications. Children with COVID-19 might present with many symptoms, a few symptoms, or be asymptomatic. The most common symptoms in children are fever and dry cough, and other common symptoms include nasal congestion or a runny nose, fatigue, and headache. Evidence suggests that many children develop long-term COVID-19. As of September 22, 2020, no vaccine trials were conducted on children under 18 years. According to the CDC, adolescents aged 16 or 17 are eligible for the Pfizer COVID-19 vaccine, but not Moderna or Janssen (Johnson & Johnson) vaccines. As of March 2021, Moderna and Pfizer/Biotech had begun vaccine trials on children, and Johnson & Johnson planned to do the same. Children and adolescents are generally at a lower risk of infection, and if an infection occurs, it is likely to be mild. However, some children and young people have had severe experiences with the disease, and a few have died. COVID-19-related measures have a profound effect on health and well-being, and for some, the impact will be lifelong.}, keywords = {COVID-19,children,Symptoms,Prevention,Vaccine}, url = {https://www.health-providers.ir/article_148878.html}, eprint = {https://www.health-providers.ir/article_148878_660c4982276c4c2f59e2dcc5227216c7.pdf} }